Highlights Merck & Co., Inc.

Equities

MRK

US58933Y1055

Market Closed - Nyse Other stock markets 04:00:02 2024-04-26 pm EDT			5-day change	1st Jan Change
131.2 ^USD	+0.37%		+4.31%	+20.34%

Apr. 26	Wolfe Research Adjusts Price Target on Merck & Company to $151 From $141	MT
Apr. 26	Morgan Stanley Adjusts Merck & Co.'s Price Target to $132 From $128	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

AbbVie raises annual profit forecast on strong Skyrizi sales	Apr. 26	RE
Top Midday Stories: Shares of Meta, IBM, Caterpillar, Comcast and Southwest Down Big Post-Earnings; AstraZeneca Shares See Post-Earnings Bump	Apr. 25	MT
Global markets live: Ford, Dow, American Airlines, Comcast, Apple, IBM, Cisco...	Apr. 25
The specter of stagflation rears its ugly head again	Apr. 25
Merck Lifts Full-Year 2024 Outlook Following First-Quarter Beat	Apr. 25	MT
Merck raises annual target ranges	Apr. 25	CF
Merck Non-GAAP Earnings, Sales Rise; 2024 Guidance Raised	Apr. 25	MT
(MRK) MERCK & CO. Expects Fiscal Year 2024 EPS Range $8.53 - $8.65	Apr. 25	MT
Earnings Flash (MRK) MERCK & CO. Reports Q1 Revenue $15.78B	Apr. 25	MT
Earnings Flash (MRK) MERCK & CO. Posts Q1 EPS $2.07	Apr. 25	MT
Merck & Co., Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 25	CI
Merck & Co., Inc. Provides Earnings Guidance for Full-Year 2024	Apr. 25	CI
Merck raises 2024 profit forecast on strong cancer, HPV drugs sales	Apr. 25	RE
Scholz promises support for pharma sector in Germany as Merck invests	Apr. 25	RE
Hipgnosis' bidding war intensifies as Concord hikes offer for Shakira music owner	Apr. 25	RE
Hanmi Pharmaceutical Enters into Clinical Trial Collaboration and Supply Agreement with Merck & Co., Inc. to Evaluate BH3120 in Combination with KEYTRUDA®? (pembrolizumab)	Apr. 23	CI
Merck Says Health Canada Approved Keytruda Plus Fluoropyrimidine, Platinum-Containing-Chemotherapy for Gastric Cancer	Apr. 19	MT
S&P 500 ends slightly higher as markets brace for inflation data, earnings	Apr. 09	RE
Moderna Shares Rise Following Positive Results of Head and Neck Cancer Vaccine in Early Study	Apr. 09	MT
Moderna jumps as personalized cancer vaccine shows benefit in early study	Apr. 09	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Merck & Co., Inc.

Equities

MRK

US58933Y1055

Highlights

Filters